Meme kanseri hücre hatlarında liraglutid'in apoptoz üzerine olan etkilerinin araştırılması
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Yüksek kan şekeri seviyeleri, meme kanseri hücrelerinin büyümesi için uygun ortam sağlamakta ve diyabetli hastalarda meme kanseri riskini artırmaktadır. Diyabet tedavisinin meme kanseri hücrelerinin tedavisinde de etkili olabileceği ileri sürülmektedir. Bu çalışmada diyabet tedavisinde kullanılan GLP-1 agonisti liraglutidin meme kanseri tedavisinde kullanılabilirliğini araştırmak ve liraglutidin meme kanseri hücrelerinde apoptoz miktarını tespit etmek amaçlanmıştır. Materyal ve Metod: Bu çalışmada, MDA-MB-231, MCF-7 meme kanseri hücreleri kullanılmıştır. Uygulanan liraglutid tedavisiyle hücre proliferasyonundaki değişimler MTS testi ile analiz edilmiştir. Hücre ölümündeki rolünün aydınlatılması için western blotting yöntemi ve annexin PI boyama testi kullanılmıştır. Bulgular: MDA-MB-231 ve MCF-7 hücreleri, sırasıyla 3400 nM ve 4800 nM liraglutid ile 72 saat boyunca inkübe edilmiştir. Liraglutid uygulanan gruplarda ki apoptoz miktarı tedavisiz gruba göre MDA-MB-231 hücresinde 8 kat, MCF-7 hücresinde 47 kat artmıştır. Tüm sonuçlar t-testi kullanılarak analiz edilmiş ve p<0.05 olarak bulunmuştur. Sonuç: Liraglutidin MDA-MB-231 ve MCF-7 meme kanseri hücrelerinin proliferasyonunu azaltıcı ve bu hücrelerde apoptozu uyarıcı etkisinin olduğu saptanmıştır. Bu sonuçlar, liraglutidin meme kanseri tedavisinde yeni bir tedavi seçeneği olarak kullanılabileceği umudunu artırmaktadır. Anahtar Kelimeler: Apoptoz, Liraglutid, Meme Kanseri
Aim: High blood sugar levels provide a suitable environment for the growth of breast cancer cells and increase the risk of breast cancer in patients with diabetes. It is suggested that diabetes treatment may also be effective in the treatment of breast cancer cells. In this study, it was aimed to investigate the use of the GLP-1 agonist liraglutide, which is used in the treatment of diabetes, in the treatment of breast cancer and to determine the amount of apoptosis of liraglutide in breast cancer cells. Material and Method: In this study, MDA-MB-231, MCF-7 breast cancer cells were used. Cell proliferation of this treatment in cells with applied liraglutide treatment was tested with MTS. Western blotting method and annexin PI staining test were used to elucidate its role in cell death. Results: MDA-MB-231 and MCF-7 cells were incubated for 72 hours with different concentrations of liraglutide 3400 nM and 4800 nM, respectively. The amount of apoptosis in the liraglutide treated groups increased 8 times in MDA-MB-231 cells and 47 times in MCF-7 cells compared to the untreated group. All results were analyzed using the t-test and found p<0.05. Conclusion: Liraglutide has been found to reduce proliferation of MDA-MB-231 and MCF-7 breast cancer cells and stimulate apoptosis in these cells. These results raise the hope that liraglutide can be used as a new treatment option in the treatment of breast cancer. Keywords: Apoptosis, Liraglutide, Breast Cancer
Aim: High blood sugar levels provide a suitable environment for the growth of breast cancer cells and increase the risk of breast cancer in patients with diabetes. It is suggested that diabetes treatment may also be effective in the treatment of breast cancer cells. In this study, it was aimed to investigate the use of the GLP-1 agonist liraglutide, which is used in the treatment of diabetes, in the treatment of breast cancer and to determine the amount of apoptosis of liraglutide in breast cancer cells. Material and Method: In this study, MDA-MB-231, MCF-7 breast cancer cells were used. Cell proliferation of this treatment in cells with applied liraglutide treatment was tested with MTS. Western blotting method and annexin PI staining test were used to elucidate its role in cell death. Results: MDA-MB-231 and MCF-7 cells were incubated for 72 hours with different concentrations of liraglutide 3400 nM and 4800 nM, respectively. The amount of apoptosis in the liraglutide treated groups increased 8 times in MDA-MB-231 cells and 47 times in MCF-7 cells compared to the untreated group. All results were analyzed using the t-test and found p<0.05. Conclusion: Liraglutide has been found to reduce proliferation of MDA-MB-231 and MCF-7 breast cancer cells and stimulate apoptosis in these cells. These results raise the hope that liraglutide can be used as a new treatment option in the treatment of breast cancer. Keywords: Apoptosis, Liraglutide, Breast Cancer
Açıklama
Anahtar Kelimeler
Tıbbi Biyoloji, Medical Biology
